FDA Fast Track for Telix
FDA Grants Fast Track Status to Telix BiPASS Prostate Cancer Imaging Program
Anonymous
Key Points
1
The Phase 3 study enrolled 350 patients, and Telix said enrollment was completed on Sept. 2; the trial listing describes potential participants as biopsy-naive men with suspected prostate cancer who are scheduled for a template biopsy.
2
Illuccix and Gozellix already have U.S. approval for PET imaging of PSMA-positive lesions in men with prostate cancer and suspected metastasis or recurrence. BiPASS is testing their use earlier in the diagnostic pathway, before biopsy.
3
Fast Track status can make rolling submission of completed sections of an NDA available; priority review would require meeting separate criteria, according to the FDA information cited in the article.
4
BiPASS is a prospective, open-label trial conducted at sites in the United States and Australia.
Telix Pharmaceuticals has secured FDA Fast Track designation for BiPASS, a program studying whether combining PET imaging with MRI before prostate biopsy can better detect dangerous cancers. BioPharma APAC The Phase 3 trial enrolled 350 men with suspected prostate cancer and completed enrollment in early September. Fast Track status allows more frequent conversations with the FDA and could enable rolling submission of study data, though it does not guarantee faster approval or guarantee the imaging approach will work.
Two PSMA-PET imaging drugs already have U.S. approval for finding prostate cancer that has spread, according to Radiology Business, but BiPASS tests their use much earlier—before biopsy. Earlier research suggests the combined imaging approach could prevent nearly 50% of unnecessary biopsies, though BiPASS results have not yet been reported.
What BiPASS Is Testing
BiPASS evaluates gallium-68 PSMA-PET imaging paired with MRI in biopsy-naive men with suspected prostate cancer. BioPharma APAC The trial is open-label, meaning doctors and patients know they are receiving imaging. Study sites span the United States and Australia. The approach targets men scheduled for biopsy to see if imaging can help detect high-risk cancers and avoid unnecessary procedures.
Telix is exploring a pre-biopsy use for existing drugs. Illuccix and Gozellix already carry FDA approval for detecting prostate cancer spread in men after diagnosis, Radiology Business reported. BiPASS shifts this earlier—testing whether the same imaging tools can guide the initial biopsy decision.
What Fast Track Designation Actually Means
Fast Track is not approval. The FDA grants it to drugs targeting serious diseases where preliminary evidence shows benefit. OncoDaily It allows Telix to submit completed NDA sections as they finish, rather than waiting for the entire application. Telix can also request more frequent FDA meetings during development.
Priority review remains separate and requires meeting additional FDA criteria. Radiology Business Fast Track does not guarantee faster approval. Telix has not announced BiPASS results or provided a timeline for submitting the full application to the FDA.
Earlier Research Shows Promise but BiPASS Still Needs Results
Telix cites earlier studies showing the combined PET-MRI approach reduced unnecessary biopsies by nearly 50 percent. BioPharma APAC But those findings come from research outside BiPASS. The actual Phase 3 trial results—the gold standard for FDA decisions—have not been disclosed.
Approval will depend entirely on BiPASS data. Fast Track speeds the review process if results are convincing. Benzinga Telix enrolled 350 patients and completed recruitment on September 2. When the company releases outcomes and files for approval remains unclear.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
40
Reach
53
A
AnonymousAuthor
